Finerenone and Eye Blood Vessel Health in People With Chronic Kidney Disease
Tests finerenone's effect on the retina in adults with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease
Key facts
- Where
- Alexandria, EgyptSee the site
- Phase
- Phase 4
Where in Egypt
- Alexandria universityAlexandria, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alexandria University
- Trial code
- NCT07235891
- Record updated
- 19 November 2025
- Original description
Interestingly, A hypothesis-generating analysis was conducted from two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR), suggesting a potential benefit of finerenone in the delay of progression of non-proliferative diabetic retinopathy (NPDR), independent of baseline HbA1c. Potential benefits of finerenone were also observed in the prevention of required ocular interventions. However, the studies relied on routine ophthalmological examinations done retrospectively, which may have affected data quality and certainly affected quantity. Hence, there is a compelling need to conduct randomized studies with adequate power to detect a potential benefit of finerenone in delaying retinopathy progression, particularly given the lack of alternative options for oral treatment of retinopathy.Read full original descriptionShow less
Investigating the Impact of Finerenone on Retinal Vascular Dysfunction in Patients With Chronic Kidney Disease
Interestingly, A hypothesis-generating analysis was conducted from two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR), suggesting a potential benefit of finerenone in the delay of progression of non-proliferative diabetic retinopathy (NPDR), independent of baseline HbA1c. Potential benefits of finerenone were also observed in the prevention of required ocular interventions. However, the studies relied on routine ophthalmological examinations done retrospectively, which may have affected data quality and certainly affected quantity. Hence, there is a compelling need to conduct randomized studies with adequate power to detect a potential benefit of finerenone in delaying retinopathy progression, particularly given the lack of alternative options for oral treatment of retinopathy.
Inclusion: Age: above 18 years; Diabetic and non-diabetic non-hemodialysis CKD patients (Stage 2 - Stage 4).
Exclusion: Prior/planned ocular interventions (retinal laser treatment, intravitreal injection or vitrectomy); Malignancy; Serum potassium level > 5.5 mEq/L; Patients on hemodialysis (HD); Pregnant and lactating women.